Skip to main content
Clinical Trials/JPRN-UMIN000013622
JPRN-UMIN000013622
Recruiting
未知

The study on efficacy of Rituximab in new onset Type 1 diabetes mellitus - Efficacy of RTX in new onset Type 1 DM

niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine0 sites10 target enrollmentApril 3, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Enrollment
10
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 3, 2014
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients using insulin therapy, those who were or may have been pregnant, and those with severe liver dysfunction (AST and ALT: 3 times the normal levels) were excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis. - NDRheumatoid arthritisMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2007-001754-11-ITROCHE
Active, not recruiting
Not Applicable
Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR.Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.Pacientes con artritis reumatoide (AR) activa refractarios a uno o más fármacos antiTNF (definido por un DAS28>3,2).MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2008-002381-55-ESROCHE FARMA, S.A.
Completed
Phase 2
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphoma
JPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
Active, not recruiting
Phase 1
A multi-centre pilot study of Rituximab in patients with active PsA
EUCTR2006-000844-17-SKVienna Medical University30
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-UMIN000035753agoya University Hospital27